REVIEW OF DECISIONS

BOARD MEETING 14-15 June 2017, Geneva



DECISION 1: CONSENT AGENDA: BOARD LEADERSHIP

- a) Reappointed Gunilla Carlsson as an Unaffiliated Board Member effective 1 January 2018 and until 31 December 2020; and
- **b)** Appointed Gunilla Carlsson as Vice Chair of the Board with individual signatory authority effective 1 July 2017 and until 31 December 2018.



DECISION 2: CONSENT AGENDA: BOARD & COMMITTEE MEMBER APPOINTMENTS (1/5)

- a) Appointed the following Board Members:
 - Amy Baker as Board Member representing Canada on the donor constituency anchored by Canada in the seat currently held by Susan Tolton of Canada effective immediately and until 31 December 2018.
 - Blair Exell as Board Member representing Australia on the donor constituency anchored by the United States in the seat currently held by Irene Koek of the United States effective 1 July 2017 and until 30 June 2019.
 - Clarisse Loe Loumou as Board Member representing the civil society organisations constituency in the seat currently held by Naveen Thacker effective 1 July 2017 and until 30 June 2019.



DECISION 2: CONSENT AGENDA: BOARD & COMMITTEE MEMBER APPOINTMENTS (2/5)

- Sai Prasad as Board Member representing the vaccine industry developing countries in the seat currently held by Adar Poonawalla effective 1 July 2017 and until 30 June 2020.
- Susan Silberman as Board Member representing the vaccine industry industrialised countries in the seat currently held by David Loew effective 1 August 2017 and until 31 July 2020.
- b) Reappointed the following Board Members:
 - **Stephen Zinser** as an Unaffiliated Board Member effective 1 July 2017 and until 30 June 2020.



DECISION 2: CONSENT AGENDA: BOARD & COMMITTEE MEMBER APPOINTMENTS (3/5)

- c) Appointed the following Alternate Board Members:
 - Irene Koek as Alternate Board Member representing the United States on the donor constituency anchored by the United States in the seat currently held by Blair Exell of Australia effective 1 July 2017 and until 30 June 2019.
 - Craig Burgess as Alternate Board member to Clarisse Loe Loumou representing the civil society organisations constituency in the seat currently held by Clarisse Loe Loumou effective 1 July 2017 and until 30 June 2019.
 - John Roberts as Alternate Board member to Susan Silberman representing the vaccine industry industrialised countries in the seat currently held by Lyn Morgan effective 1 August 2017 and until 31 July 2020.



DECISION 2: CONSENT AGENDA: BOARD & COMMITTEE MEMBER APPOINTMENTS (4/5)

- **d)** Appointed the following to the Governance Committee:
 - Amy Baker (Board Member) in the seat currently held by Susan Tolton effective immediately and until 31 December 2017.
 - Clarisse Loe Loumou (Board Member) in the seat currently held by Naveen Thacker effective 1 July 2017 and until 31 December 2017.
 - John Roberts (Alternate Board Member) in the seat currently held by Lyn Morgan effective 1 August 2017 and until 31 December 2017.
- e) Reappointed the following to the Governance Committee:
 - Blair Exell (Board Member) effective 1 July 2017 and until 31 December 2017.



DECISION 2: CONSENT AGENDA: BOARD & COMMITTEE MEMBER APPOINTMENTS (5/5)

- **f)** Appointed the following to the Programme and Policy Committee:
 - Abdul Wali Ghaury (Committee Delegate) in the seat currently held by Ahmed Jan Naeem effective immediately and until 31 December 2017.
 - Adar Poonawalla (Committee Delegate) in the seat currently held by Rajinder Suri effective 1 July 2017 and until 31 December 2017.
- g) Reappointed the following as Chair of the Investment Committee:
 - Stephen Zinser until 31 December 2017.



DECISION 3: CONSENT AGENDA: CHANGES TO COMMITTEE CHARTERS (1/2)

- a) <u>Noted</u> the steps and actions taken to elevate Board discussions as set out in Annex B to Doc 02c;
- **b)** Approved the establishment of the All Chairs Group under the provisions of Article 20 of the Statutes as read with Article 5 of the By-Laws and the accompanying terms of reference set out in Annex C to Doc 02c, effective immediately;
- c) Noted and Approved that the Executive Committee shall be retired on 31 August 2017 with consequential amendments to the Statutes and By-Laws as more fully set out in Annex B to Doc 05;



DECISION 3: CONSENT AGENDA: CHANGES TO COMMITTEE CHARTERS (2/2)

- d) <u>Approved</u> the establishment of the Market-Sensitive Decisions Committee under the provisions of Article 19 of the Statutes as read with Article 4 of the By-Laws and the accompanying Charter set out in Annex D to Doc 02c, effective from 1 September 2017;
- e) <u>Approved</u> the revised and updated Charter for the Programme and Policy Committee set out in Annex E to Doc 02c, effective from 1 January 2018; and
- f) <u>Approved</u> the revised and updated Charter for the Governance Committee set out in Annex F to Doc 02c, effective from 1 January 2018.



DECISION 4: CONSENT AGENDA: REVIEW OF STATUTES AND BY-LAWS

The Gavi Alliance Board:

Approved the amendments to the Statutes and By-Laws of the Gavi Alliance as set out in Annex B to Doc 02d.



DECISION 5: CONSENT AGENDA: GAVI POLICY: FRAGILITY, EMERGENCIES AND REFUGEES

The Gavi Alliance Board:

<u>Approved</u> the Gavi Policy: Fragility, Emergencies, Refugees, attached as Annex A, to Doc 02e, as amended by discussions at the PPC, which will replace the 2013 Fragility and Immunisation Policy.



DECISION 6: CONSENT AGENDA: REVIEW OF COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM

- a) <u>Approved</u> the approach to equitable allocation of available CCEOP funding based on the HSS formula as described in Section 2.2 of Doc 02f.
- **b)** Requested the Secretariat to continue documenting lessons to provide regular updates on the progress of the CCEOP to the Programme and Policy Committee.



DECISION 7: CONSENT AGENDA: PROGRAMME FUNDING POLICY

The Gavi Alliance Board:

Approved the amended Gavi Alliance Programme Funding Policy attached as Annex A to Doc 02g.



DECISION 8: FINANCIAL UPDATE

The Gavi Alliance Board:

Approved, within the overall Partnership Engagement Framework, a budget of:

- (i) US\$ 19.0 million for UNICEF Supply Division fees for the procurement of vaccines and related devices in 2018; and
- (ii) US\$ 2.4 million for UNICEF Supply Division fees for the procurement of cold chain equipment in 2018.



DECISION 9: COUNTRY PROGRAMMES: STRATEGIC ISSUES

The Gavi Alliance Board:

<u>Found</u> that exceptional circumstances in Yemen justify the continuation of Gavi support irrespective of its default status on its 2016 co-financing obligations.



DECISION 10: REVIEW OF RISK APPETITE STATEMENT AND RISK MANAGEMENT UPDATE

The Gavi Alliance Board:

Approved the updated Risk Appetite Statement attached as Annex A to Doc 11, as amended by discussions at the Board.



DECISION 11: GAVI'S POTENTIAL ENGAGEMENT IN IPV POST 2018

The Gavi Alliance Board, recognising that the Secretariat should work with GPEI and countries to enable the implementation of SAGE guidance on fIPV and missed children:

<u>Approved</u> extending Gavi's support for IPV from 2018 to 2020 under the arrangements agreed by the Board in November 2013, and subject to polio-specific funding being available.



Thank you



